The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Eichbaum, Michael ^a   Mayer, Christine ^a   Eickhoff, Regina ^b   Bischofs, Esther ^a   Gebauer, Gerhard ^c   Fehm, Tanja ^d   Lenz, Florian ^e   Fricke, Hans Christian ^f   Solomayer, Erich ^g   Fersis, Nikos ^h   Schmidt, Marcus ⁱ   Wallwiener, Markus ^a   Schneeweiss, Andreas ^a,j   Sohn, Christof ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ALCEDIS GMBH   (Germany)

^c Marienkrankenhaus Hamburg   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e Krankenhaus Hetzelstift   (Germany)

^f KLINIKUM KONSTANZ   (Germany)

^g SAARLAND UNIVERSITY   (Germany)

^h KLINIKUM CHEMNITZ   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PAZOPANIB; ANTINEOPLASTIC AGENT; PLATINUM; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER SURVIVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPIGMENTATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATURIA; HEMORRHAGIC COLITIS; HEMORRHAGIC CYSTITIS; HISTOLOGY; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; MOUTH ULCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPTIMAL DRUG DOSE; OVARY CANCER; PERIPHERAL EDEMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RASH; SIDE EFFECT; SKIN INFLAMMATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; UTERINE TUBE CARCINOMA; VOMITING; CLINICAL TRIAL; DRUG RESISTANCE; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM; PYRIMIDINES; SULFONAMIDES;

EID: 80054688412     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-453     Document Type: Article

References (32)

1. GEKID-Atlas: Inzidenz und Mortalität von Krebserkrankungen in den Bundesländern. , http://www.ekr.med.uni-erlangen.de/GEKID/Atlas/CurrentVersion/Inzidenz/atlas.html
2. GEKID-Atlas: Inzidenz und Mortalität von Krebserkrankungen in den Bundesländern. , http://www.ekr.med.uni-erlangen.de/GEKID/Atlas/CurrentVersion/Mortalitaet/atlas.html
3. McGuire WP, Brady MF, Ozols RF. The Gynecologic Oncology Group experience in ovarian cancer. Ann Oncol 1999, 10:29-34.
4. McGuire WP. Primary therapy of epithelial ovarian cancer. Amer Soc Clin Oncol Educational Book 2001, 477-480. Spring.
5. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361(9375):2099-106.
6. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Ovarian cancer. Crit Rev Oncol Hematol 2006, 60(2):159-79. 10.1016/j.critrevonc.2006.03.004, 17018256.
7. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer 2001, 7:427-436.
8. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low dose (metronomic) cyclyophoshphamide administered continuously through the drinking water. Cancer Res 2002, 62:2731-2735.
9. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003, 100:12917-12922,. 10.1073/pnas.2135406100, 240719, 14561896.
10. Colleoni M, Rocca A, Sandri T, et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80. 10.1093/annonc/mdf013, 12401670.
11. Samaritini R, Corrado G, Vizza E, Sbiroli C. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer 2001, 7:65.
12. Bello L, Carrabba G, Giussani C, et al. Low dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001, 61:501-506.
13. Klement G, Baruchel S, Rak J, et al. Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:R15-24. 10.1172/JCI8829, 517491, 10772661.
14. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-vegfr-2 antibody in multidrug resistant human breastcancer xenografts. Clin Cancer Res 2002, 8:221-232.
15. Takahashi N, Haba A, Matsuno F, et al. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by antiendoglin (CD105) monoclonal antibodies and synergy between antiendoglin antibody and cyclophosphamide. Cancer Res 2001, 61:846-854.
16. Chura JC, Van Iseghem K, Downs LS, et al. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007, 107:326-30. 10.1016/j.ygyno.2007.07.017, 17706754.
17. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26:76-82. 10.1200/JCO.2007.12.1939, 18165643.
18. Jurado García JM, Sánchez A, Pajares B, Pérez E, Alonso L, Alba E. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 2008, 10:583-6. 10.1007/s12094-008-0254-7, 18796376.
19. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1):27-31. 10.1038/nm0195-27, 7584949.
20. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008, 5(4):194-204.
21. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82:4-6. 10.1093/jnci/82.1.4, 1688381.
22. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. Phase I Trial of Pazopanib in Patients with Advanced Cancer. Clin Cancer Res 2009, 15:4220-4227. 10.1158/1078-0432.CCR-08-2740, 19509175.
23. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in Locally Advanced or Metastatic Renal Cell: Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010, 28:1061-1068. 10.1200/JCO.2009.23.9764, 20100962.
24. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009, 27(19):3126-32. 10.1200/JCO.2008.21.3223, 19451427.
25. Slamon D, Gomez H, Amit O, Richie M, Pandite L, Roychowdhury D, Goodman V. Updated Results From a Randomized Study in Patients With First-line ErbB2-positive Advanced or Metastatic Breast Cancer. ESMO Congress 2008, 1233. [abstract].
26. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010, 28(19):3131-7. 10.1200/JCO.2009.23.9749, 20516450.
27. Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010, 28(22):3562-9. 10.1200/JCO.2009.26.9571, 20606083.
28. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010, 119:32-37. 10.1016/j.ygyno.2010.05.033, 20584542.
29. Simon R. Optimal two-stage designs for phase II clinical trials. Contr Clin Trials 1989, 10:1-10.
30. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995, 14:1149-61. 10.1002/sim.4780141102, 7667557.
31. Rustin GJS. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003, 21:187-203.
32. Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004, 95:686-90. 10.1016/j.ygyno.2004.09.005, 15581982.